N-pentyl-N-[[2'-[N-(triphenylmethyl)tetrazol-5-yl]-1,1'-biphenyl-4-yl]methyl]amine | 141872-29-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N-pentyl-N-[[2'-[N-(triphenylmethyl)tetrazol-5-yl]-1,1'-biphenyl-4-yl]methyl]amine
• 英文别名: N-pentyl-N-[[2'-(N-trityltetrazol-5-yl)biphenyl-4-yl]methyl]amine；pentyl(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl)amine；pentyl[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]amine；N-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]pentan-1-amine
• CAS: 141872-29-9
• 化学式: C₃₈H₃₇N₅
• 分子量: 563.745
• InChiKey: SERCXMIJEDICSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-pentyl-N-[[2'-[N-(triphenylmethyl)tetrazol-5-yl]-1,1'-biphenyl-4-yl]methyl]amine 在 N,N-二异丙基乙胺 作用下， 以27%的产率得到1-[N-pentyl-N-[[2'-(N-trityltetrazol-5-yl)biphenyl-4-yl]methyl]carbamoyl]-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines

  摘要：

  结构I的联苯甲胺的氨基甲酰和氧基甲酰衍生物是一种具有平衡AT.sub.1和AT.sub.2活性的抗血管紧张素II拮抗剂，可用于治疗高血压和相关疾病以及眼压增高。其中X为--O--或--N(R.sup.7)--。

  公开号：

  US05312820A1
• 作为产物：
  描述：

  5-(4'METHYLVALERAMIDE-BIPHENYl-2-YL)-1-TRITYL-1H-TETRAZOLE 在 lithium aluminium tetrahydride 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以100%的产率得到N-pentyl-N-[[2'-[N-(triphenylmethyl)tetrazol-5-yl]-1,1'-biphenyl-4-yl]methyl]amine
  参考文献：
  名称：

  BIPHENYL DERIVATIVES

  摘要：

  公开号：

  EP1354871B1

文献信息

• [EN] DUAL-ACTING ANTIHYPERTENSIVE AGENTS<br/>[FR] AGENTS ANTIHYPERTENSIFS À DOUBLE ACTION
  申请人：THERAVANCE INC

  公开号：WO2009035543A1

  公开（公告）日：2009-03-19

  The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下公式的化合物：(I) 其中：Ar、r、R3、Z、X和R5-7按说明书定义，或其药用可接受盐。这些化合物具有AT1受体拮抗活性和中性内肽酶抑制活性。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Biphenyl derivatives
  申请人：——

  公开号：US20040048909A1

  公开（公告）日：2004-03-11

  Biphenyl derivatives represented by the following formula (1): 1 wherein R 1 represents a C 5-7 alkyl group, R 2 represents a substituted or unsubstituted aromatic hydrocarbon, or cycloalkyl group, R 3 represents a tetrazolyl group, —NHCOCF 3 , —NHSO 2 CF 3 or —SO 2 NHCONHR 4 in which R 4 represents a substituted or unsubstituted aromatic hydrocarbon group, and Z represents a single bond, a C 1-4 alkylene group or —SO 2 NH—, and salts thereof; and ACAT inhibitors and medicines containing them as active ingredients. The compounds according to the present invention possess excellent ACAT inhibitory activities, and are useful as preventives and/or therapeutics for diseases cased by the enhancement of ACAT activity, for example, hypercholesterolemia, atherosclerosis and the like.

  以下为式（1）所表示的联苯衍生物：其中，R1代表C5-7烷基；R2代表取代或未取代的芳香烃或环烷基；R3代表四唑基、—NHCOCF3、—NHSO2CF3或—SO2NHCONHR4，其中R4代表取代或未取代的芳香烃基；Z代表单键、C1-4烷基或—SO2NH—，以及其盐；以及含有它们作为活性成分的ACAT抑制剂和药物。本发明的化合物具有优异的ACAT抑制活性，可用作预防和/或治疗由ACAT活性增强引起的疾病，例如高胆固醇血症、动脉硬化等。
• Dual-acting antihypertensive agents
  申请人：Choi Seok-Ki

  公开号：US20090093417A1

  公开（公告）日：2009-04-09

  The invention relates to compounds having the formula: wherein: Ar, r, R 3 , Z, X, and R 5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下式的化合物：其中：Ar，r，R3，Z，X和R5-7如规范中所定义，或其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和脑利钠肽酶抑制活性。本发明还涉及包含这种化合物的制药组合物；使用这种化合物的方法；以及制备这种化合物的过程和中间体。
• DUAL-ACTING ANTIHYPERTENSIVE AGENTS
  申请人：CHOI Seok-Ki

  公开号：US20120088919A1

  公开（公告）日：2012-04-12

  The invention relates to compounds having the formula: wherein: Ar, r, R 3 , Z, X, and R 5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及如下公式的化合物：其中：Ar、r、R3、Z、X和R5-7如规范中所定义，或其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和内肽酶抑制活性。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• US5312820A
  申请人：——

  公开号：US5312820A

  公开（公告）日：1994-05-17